Back to Search
PATRICIA LORUSSO, DO
DO
Medical Oncology Physician
NPI: 1932146420IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
5101008202(MI)
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
5101008202(MI)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
MICHIGAN STATE UNIVERSITY COLLEGE OF OSTEOPATHIC MEDICINE
Class of 1981
Research & Publications (20)
Toward evidence-based management of the dermatologic effects of EGFR inhibitors.
PMID 19323301·Oncology (Williston Park)·2009
8-other
Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer.
PMID 18565892·J Clin Oncol·2008
3-trial
Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors.
PMID 18219445·Invest New Drugs·2008
3-trial
Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumors.
PMID 18574557·Invest New Drugs·2008
3-trial
Bioavailability and pharmacokinetics of the investigational anticancer agent XK469 (NSC 698215) in rats following oral and intravenous administration.
PMID 15592839·Cancer Chemother Pharmacol·2005
7-preclinical
Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.
PMID 16009947·J Clin Oncol·2005
3-trial
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.
PMID 12796366·Clin Cancer Res·2003
8-other
Phase I studies of ZD1839 in patients with common solid tumors.
PMID 12644981·Semin Oncol·2003
6-review
Phase I clinical trial of 5-fluoro-pyrimidinone (5FP), an oral prodrug of 5-fluorouracil (5FU).
PMID 12003195·Invest New Drugs·2002
3-trial
Analysis of skeletal-related events in breast cancer and response to therapy.
PMID 11544572·Semin Oncol·2001
6-review
Oxaliplatin in tumors other than colorectal cancer.
PMID 11204661·Oncology (Williston Park)·2000
6-review
Phase I pharmacokinetic study of the novel antitumor agent SR233377.
PMID 10955788·Clin Cancer Res·2000
3-trial
Phase 0 clinical trials: an answer to drug development stagnation?
PMID 19364952·J Clin Oncol·2009
8-other
Theoretical and practical application of traditional and accelerated titration Phase I clinical trial designs: the Wayne State University experience.
PMID 19384685·J Biopharm Stat·2009
8-other
Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate aminoflavone (NSC 686288) in human plasma.
PMID 19349217·J Chromatogr B Analyt Technol Biomed Life Sci·2009
4-observational
Pulmonary metastasis of basal cell carcinoma: a rare manifestation of a common disease with variable clinical course.
PMID 19633477·J Thorac Oncol·2009
5-case
Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
PMID 19318488·Clin Cancer Res·2009
6-review
Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology.
PMID 18549338·Expert Opin Investig Drugs·2008
6-review
Effect of food on the pharmacokinetic behavior of the potent oral taxane BMS-275183.
PMID 18593998·Clin Cancer Res·2008
3-trial
Phase I dose-escalation study of the thioxanthone SR271425 administered intravenously once every 3 weeks in patients with advanced malignancies.
PMID 18449472·Invest New Drugs·2008
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 4100 JOHN R ST
DETROIT, MI 48201 - Phone
- (800) 527-6266
Quick Facts
- NPI
- 1932146420
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 45
- Publications
- 20
Are you this provider?
Claim Your Profile